Search research articles
Contact Us
Filters
Showing results (141-150 of 175) with videos related to
Page
of 18
Sort By:
Leukemia
|
October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
N C Gutiérrez, M V Castellanos, M L Martín, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2008
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy
Gema Mateo, M Angeles Montalbán, Maria-Belén Vidriales, et al.
Annals of Hematology
|
November 28, 2009
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Carlos Santamaría, María C Chillón, Ramón García-Sanz, et al.
Hemasphere
|
December 16, 2024
Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients
Cristina De Ramón, Elizabeta A Rojas, Irena Misiewicz-Krzeminska, et al.
Scientific Reports
|
December 23, 2021
Clinical evaluation of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2
Maria D Ferrer, Álvaro Sánchez Barrueco, Yolanda Martinez-Beneyto, et al.
Leukemia
|
July 18, 2013
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N Puig, M E Sarasquete, A Balanzategui, et al.
Blood
|
August 16, 2011
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
Antonio Palumbo, Sara Bringhen, Heinz Ludwig, et al.
Leukemia
|
November 4, 2017
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
P Arana, B Paiva, M-T Cedena, et al.
Leukemia
|
June 8, 2013
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control
B Paiva, M-B Vídriales, L Rosiñol, et al.
Blood
|
August 2, 2008
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva, Maria-Belén Vidriales, Jorge Cerveró, et al.
Page
of 18
Search research articles
Search
Showing results (141-150 of 175) with videos related to
Sort By:
Page
of 18
Leukemia
|
October 7, 2006
Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis
N C Gutiérrez, M V Castellanos, M L Martín, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 30, 2008
Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy
Gema Mateo, M Angeles Montalbán, Maria-Belén Vidriales, et al.
Annals of Hematology
|
November 28, 2009
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Carlos Santamaría, María C Chillón, Ramón García-Sanz, et al.
Hemasphere
|
December 16, 2024
Expression profile of Bcl-2 family proteins in newly diagnosed multiple myeloma patients
Cristina De Ramón, Elizabeta A Rojas, Irena Misiewicz-Krzeminska, et al.
Scientific Reports
|
December 23, 2021
Clinical evaluation of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2
Maria D Ferrer, Álvaro Sánchez Barrueco, Yolanda Martinez-Beneyto, et al.
Leukemia
|
July 18, 2013
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
N Puig, M E Sarasquete, A Balanzategui, et al.
Blood
|
August 16, 2011
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)
Antonio Palumbo, Sara Bringhen, Heinz Ludwig, et al.
Leukemia
|
November 4, 2017
Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials
P Arana, B Paiva, M-T Cedena, et al.
Leukemia
|
June 8, 2013
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control
B Paiva, M-B Vídriales, L Rosiñol, et al.
Blood
|
August 2, 2008
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Bruno Paiva, Maria-Belén Vidriales, Jorge Cerveró, et al.
Page
of 18